Skip to main content
Premium Trial:

Request an Annual Quote

GSK to Test-Run Procognia’s Protein Arrays for Kinase-Screening Studies

NEW YORK (GenomeWeb News) – Procognia said today that GlaxoSmithKline will use its protein arrays to profile kinase kits in drug development research.
Under the agreement, GSK will use Procognia’s protein array technology with its own kinase inhibitors in profiling studies to assess whether it can integrate these arrays into its screening process.
GSK will have use of “over 300 functional kinases,” Procognia said. The Maidenhead, UK-based company said it hopes to “have a functional human protein array containing the entire human kinome” in the second quarter of this year.
Procognia also said its protein arrays are used for biomarker discovery, protein interaction, and in identifying substrates.
Financial terms of the agreement were not released.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.